Pace sets Zealand apart from larger rivals
Zealand Pharma’s CEO, Britt Meelby Jensen, is pleased with the positive data her company published from a phase 2 study last week. But she is even more pleased that the organization has powered through the clinical phase at a pace that sets the biotech apart from many larger corporations.
BY STEFAN SINGH KAILAY
Zealand Pharma has a stated ambition to advance its proprietary projects most of the way through clinical development without having to partner. And in that light, CEO Britt Meelby Jensen is especially pleased with last week’s announcement about positive data from a phase 2 trial with the candidate dasiglucagon as rescue treatment of severe hypoglycemia in insulin dependent diabetic patients.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand Pharma strikes deal with German company
For abonnenter
